analyzed pan-cancer datasets and discovered that mutations within the dsRNA-binding domain of ADAR1—particularly the R767 substitution impair dsRNA recognition, disrupt immune surveillance, and may promote tumor progression (92). This evidence concerns the gene ADAR and cancer.